For alle (100%) splenektomerede patienter, som fik romiplostim, kunne dosis reduceres med mere end 25%, eller samtidig medicinsk behandling af ITP kunne ophøre ved afslutningen af behandlingsperioden sammenlignet med 17% af de patienter, som blev behandlet med placebo.
All (100%) splenectomised patients who were receiving romiplostim were able to reduce the dose by more than 25% or discontinue the concurrent ITP medical therapies by the end of the treatment period compared to 17% of placebo treated patients.